Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C

Virology

Volumn 377, Issue 1, 2008, Pages 71-79

  Wang, Tao ^a   Zhang, Wenyan ^a,b   Tian, Chunjuan ^b   Liu, Bindong ^a   Yu, Yunkai ^a   Ding, Lingmei ^c   Spearman, Paul ^c   Yu, Xiao Fang ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JILIN UNIVERSITY   (China)

^c EMORY UNIVERSITY   (United States)

Author keywords

APOBEC3C; APOBEC3G; Cytidine deaminase; HIV 1; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; GAG PROTEIN; GENOMIC RNA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; VIRION; VIRUS NUCLEOCAPSID; VIRUS PARTICLE;

BASE SEQUENCE; CELL LINE; CYTIDINE DEAMINASE; DNA PRIMERS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, GAG; HIV-1; HUMANS; PROTEIN BINDING; RNA, VIRAL; SEQUENCE DELETION; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 44949182656     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.04.012     Document Type: Article

References (88)

1. Alce T.M., and Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279 33 (2004) 34083-34086
2. Berkowitz R., Fisher J., and Goff S.P. RNA packaging. Curr. Top. Microbiol. Immunol. 214 (1996) 177-218
3. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5 11 (2004) 1109-1115
4. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 17 (2006) 8450-8458
5. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K S., Moran J.V., and Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103 23 (2006) 8780-8785
6. Bonvin M., Achermann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S., Vartanian J.P., and Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43 6 (2006) 1364-1374
7. Bukrinskaya A.G., Vorkunova G.K., and Tentsov Y. HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA. AIDS Res. Hum. Retrovir. 8 10 (1992) 1795-1801
8. Burnett A., and Spearman P. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81 10 (2007) 5000-5013
9. Burniston M.T., Cimarelli A., Colgan J., Curtis S.P., and Luban J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J. Virol. 73 10 (1999) 8527-8540
10. Cen S., Guo F., Niu M., Saadatmand J., Deflassieux J., and Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279 32 (2004) 33177-33184
11. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., and Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 5 (2006) 480-485
12. Chiu Y.L., and Greene W.C. APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J. Biol. Chem. 281 13 (2006) 8309-8312
13. Chiu Y.L., Witkowska H.E., Hall S.C., Santiago M., Soros V.B., Esnault C., Heidmann T., and Greene W.C. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103 42 (2006) 15588-15593
14. Conticello S.G., Harris R.S., and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13 22 (2003) 2009-2013
15. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80 3 (2006) 1067-1076
16. Dang Y., Wang X., Esselman W.J., and Zheng Y.H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 21 (2006) 10522-10533
17. Dettenhofer M., and Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73 2 (1999) 1460-1467
18. Dong X., Li H., Derdowski A., Ding L., Burnett A., Chen X., Peters T.R., Dermody T.S., Woodruff E., Wang J.J., and Spearman P. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 120 5 (2005) 663-674
19. Douaisi M., Dussart S., Courcoul M., Bessou G., Vigne R., and Decroly E. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem. Biophys. Res. Commun. 321 3 (2004) 566-573
20. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A.J., Heidmann T., and Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433 7024 (2005) 430-433
21. Goff S.P. Retrovirus restriction factors. Mol. Cell 16 6 (2004) 849-859
22. Guo F., Cen S., Niu M., Saadatmand J., and Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80 23 (2006) 11710-11722
23. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev., Immunol. 4 11 (2004) 868-877
24. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 6 (2003) 803-809
25. Hulme A.E., Bogerd H.P., Cullen B.R., and Moran J.V. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390 1-2 (2007) 199-205
26. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., and Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35 21 (2007) 7096-7108
27. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., and Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 3 (2002) 285-296
28. Kaiser S.M., and Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80 2 (2006) 875-882
29. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., and Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79 9 (2005) 5870-5874
30. Kobayashi M., Takaori-Kondo A., Miyauchi Y., Iwai K., and Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J. Biol. Chem. 280 19 (2005) 18573-18578
31. Langlois M.A., Beale R.C., Conticello S.G., and Neuberger M.S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33 6 (2005) 1913-1923
32. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 5622 (2003) 1112
33. Lee Y.M., and Yu X.F. Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells. Virology 243 1 (1998) 78-93
34. Li X.Y., Guo F., Zhang L., Kleiman L., and Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282 44 (2007) 32065-32074
35. Liu B., Yu X., Luo K., Yu Y., and Yu X.F. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78 4 (2004) 2072-2081
36. Liu B., Sarkis P.T., Luo K., Yu Y., and Yu X.F. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79 15 (2005) 9579-9587
37. Lochrie M.A., Waugh S., Pratt Jr. D.G., Clever J., Parslow T.G., and Polisky B. In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein. Nucleic Acids Res. 25 14 (1997) 2902-2910
38. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., and Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78 21 (2004) 11841-11852
39. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., and Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81 13 (2007) 7238-7248
40. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., and Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102 32 (2005) 11444-11449
41. Malim M.H. Natural resistance to HIV infection: The Vif-APOBEC interaction. C. R. Biol. 329 11 (2006) 871-875
42. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 6944 (2003) 99-103
43. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 1 (2003) 21-31
44. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9 11 (2003) 1398-1403
45. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., and Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 13 (2007) 7099-7110
46. Mehle A., Goncalves J., Santa-Marta M., McPike M., and Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18 23 (2004) 2861-2866
47. Mehle A., Thomas E.R., Rajendran K.S., and Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281 25 (2006) 17259-17265
48. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., Flory E., Schumann G.G., and Munk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281 31 (2006) 22161-22172
49. Navarro F., and Landau N.R. Recent insights into HIV-1 Vif. Curr. Opin. Immunol. 16 4 (2004) 477-482
50. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., and Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 2 (2005) 374-386
51. Niewiadomska A.M., Tian C., Tan L., Wang T., Sarkis P.T., and Yu X.F. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J. Virol. 81 17 (2007) 9577-9583
52. Onafuwa-Nuga A.A., Telesnitsky A., and King S.R. 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. Rna 12 4 (2006) 542-546
53. Opi S., Kao S., Goila-Gaur R., Khan M.A., Miyagi E., Takeuchi H., and Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81 15 (2007) 8236-8246
54. Ott D.E., Coren L.V., and Gagliardi T.D. Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly. J. Virol. 79 22 (2005) 13839-13847
55. Purohit P., Dupont S., Stevenson M., and Green M.R. Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection. Rna 7 4 (2001) 576-584
56. Qiu J.T., Song R., Dettenhofer M., Tian C., August T., Felber B.K., Pavlakis G.N., and Yu X.F. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73 11 (1999) 9145-9152
57. Rose K.M., Marin M., Kozak S.L., and Kabat D. The viral infectivity factor (Vif) of HIV-1 unveiled. Trends Mol. Med. 10 6 (2004) 291-297
58. Rosler C., Kock J., Kann M., Malim M.H., Blum H.E., Baumert T.F., and von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 42 2 (2005) 301-309
59. Russell R.A., and Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81 15 (2007) 8201-8210
60. Schafer A., Bogerd H.P., and Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328 2 (2004) 163-168
61. Schrofelbauer B., Senger T., Manning G., and Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80 12 (2006) 5984-5991
62. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 6898 (2002) 646-650
63. Sheehy A.M., Gaddis N.C., and Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 11 (2003) 1404-1407
64. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., and Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1 1 (2005) e6
65. Stenglein M.D., and Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281 25 (2006) 16837-16841
66. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12 3 (2003) 591-601
67. Suspene R., Sommer P., Henry M., Ferris S., Guetard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., and Vartanian J.P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32 8 (2004) 2421-2429
68. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., and Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279 34 (2004) 35822-35828
69. Tian C., Yu X., Zhang W., Wang T., Xu R., and Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80 6 (2006) 3112-3115
70. Tian C., Wang T., Zhang W., and Yu X.F. Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res. 35 21 (2007) 7288-7302
71. Turelli P., and Trono D. Editing at the crossroad of innate and adaptive immunity. Science 307 5712 (2005) 1061-1065
72. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303 5665 (2004) 1829
73. Turelli P., Vianin S., and Trono D. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 279 42 (2004) 43371-43373
74. Wang T., Tian C., Zhang W., Luo K., Sarkis P.T., Yu L., Liu B., Yu Y., and Yu X.F. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81 23 (2007) 13112-13124
75. Wang T., Tian C., Zhang W., Sarkis P.T., and Yu X.F. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol. 375 4 (2008) 1098-1112
76. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., and Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349 2 (2006) 290-299
77. Xiao Z., Ehrlich E., Luo K., Xiong Y., and Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21 1 (2007) 217-222
78. Xiao Z., Xiong Y., Zhang W., Tan L., Ehrlich E., Guo D., and Yu X.F. Characterization of a novel cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373 3 (2007) 541-550
79. Xu R., Zhang X., Zhang W., Fang Y., Zheng S., and Yu X.F. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B × antigen mutants and hepatocellular carcinoma. Hepatology 46 6 (2007) 1810-1820
80. Yang B., Chen K., Zhang C., Huang S., and Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282 16 (2007) 11667-11675
81. Yu X. Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr. Opin. HIV AIDS 1 3 (2006) 187-193
82. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 5647 (2003) 1056-1060
83. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., and Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 51 (2004) 53379-53386
84. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 5 (2004) 435-442
85. Yu Y., Xiao Z., Ehrlich E.S., Yu X., and Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18 23 (2004) 2867-2872
86. Zennou V., Perez-Caballero D., Gottlinger H., and Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78 21 (2004) 12058-12061
87. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 6944 (2003) 94-98
88. Zhang W., Zhang X., Tian C., Wang T., Sarkis P.T., Fang Y., Zheng S., Yu X.F., and Xu R. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell. Microbiol. 10 1 (2008) 112-121